The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...

The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines. The Wegovy pill ...

The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, given skyrocketing premiums and wide variance in costs between plans.

The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.

The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...